Tirzepatide
Mounjaro · Zepbound
Dual GIP/GLP-1 agonist. FDA-approved as Mounjaro (T2D) and Zepbound (obesity). SURMOUNT/SURPASS describe branded pens, not a compounded vial. Do not stack with semaglutide. Not a recovery peptide.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight8.5/10
Approved T2D and obesity labels plus SURMOUNT/SURPASS. Ceiling 9; haircut for lean-mass loss, GI dropout, and compounded vials not being Zepbound.
Compound card
- Sequence
- Dual GIP/GLP-1 analog (LY3298176)
- Class
- Once-weekly twincretin (Mounjaro / Zepbound)
- Formula
- C225H348N48O68
- Status
- FDA-approved
How it works
Tirzepatide is the first dual GIP/GLP-1 receptor agonist - a novel mechanism that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual-agonist approach amplifies the metabolic effects beyond what GLP-1 agonism alone achieves.
Tirzepatide enhances insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. The addition of GIP receptor activation improves adipose tissue insulin sensitivity and may enhance fat oxidation. Clinical trials (SURMOUNT-1) demonstrated up to 22.5% body weight reduction at the 15 mg dose - the highest weight loss achieved by any single pharmacological agent. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management.
Source: FDA Label (Mounjaro), PMID: 35658024 (SURMOUNT-1)
Goal context
Dual agonist, still an incretin
GIP plus GLP-1 is why the weight-loss number is larger in SURMOUNT. It is still weekly titration, still GI, still lean-mass risk. The scheduler exists for a reason.
Background & History
Tirzepatide (LY3437943) was developed by Eli Lilly as the first "twincretin" - a single molecule activating both GIP and GLP-1 receptors. Approved as Mounjaro in 2022 for T2D and Zepbound in 2023 for obesity, it achieved 22.5% body weight reduction in the SURMOUNT-1 trial - surpassing all prior pharmacological weight loss agents. The GIP component improves adipose tissue insulin sensitivity and may mitigate GLP-1-induced nausea, making tirzepatide better tolerated than pure GLP-1 agonists.
Key Clinical Metrics
Peak Weight Loss
Achieved at highest maintenance dose (15mg) in SURMOUNT-1 study.
Receptor Targets
Dual-agonist mechanism significantly enhances adipocyte insulin sensitivity.
Half-Life
Maintains flat, sustained peaks over a 4 to 5-day window.
Published Trial Data
Tirzepatide Once Weekly for Treatment of Obesity
Demonstrated an unprecedented 22.5% body weight reduction in adults with obesity at the 15 mg dose over 72 weeks.
Tirzepatide 10mg / 15mg in Type 2 Diabetes
Achieved up to 15.7% total body weight reduction in adults with both type 2 diabetes and obesity.
Tirzepatide versus Semaglutide Once Weekly
Head-to-head trial showing tirzepatide 15 mg provided superior HbA1c reductions and body weight loss versus semaglutide 1 mg.
Intensive Lifestyle and Maintenance
Indicated an additional 21.1% weight loss when following intensive behavioural therapy and long-term maintenance protocols.
Research Use Cases
- ✓Understanding Mounjaro vs Zepbound vs a compounded dual-agonist cake
- ✓Why SURMOUNT percents do not transfer to an unknown fill
- ✓Not a recovery peptide and not a stack with semaglutide
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Initiation (Weeks 1-4) | 2.5 mg | once weekly | GI acclimation dose only - not a therapeutic dose. |
| Escalation (Weeks 5-8) | 5.0 mg | once weekly | First true therapeutic dose. Weight loss typically begins here. |
| Escalation Blocks | 7.5 / 10 / 12.5 mg | once weekly | Increase by 2.5mg every 4 weeks based on tolerability. |
| Maximum Maintenance | 15.0 mg | once weekly | Highest studied dose. Not all patients need to reach 15mg. |
Administration
Tirzepatide: Branded pen (Mounjaro / Zepbound) vs Compounded / research vial
- Mounjaro / Zepbound is the labeled device. STEP/SURMOUNT/label numbers describe this class of product, not a reconstituted cake.
- No reconstitution step. No BAC water. No fake 5 mg vial chart.
- SURMOUNT/SURPASS describe branded 15 mg, not a mystery 10 mg fill.
- A pen is a prescription device. Compounded or research vials are not a cheaper Wegovy with the same factory.
- Pens do not go in the reconstitution calculator.
- If you actually have a cake, vial math is the job this site will do.
- Do not stack with semaglutide. Dual agonist is still an incretin class warning.
- A cake is not the pen. Identity, sterility, and dose accuracy are on you and the compounder.
- Do not stack with another GLP-1/GIP agonist.
- Boxed-warning class (MTC/MEN2) still applies to the receptor, not only to the brand name.
Timeline
Who it is for
Obesity / Weight Management
HighFDA-approved (Zepbound). SURMOUNT-1 showed unprecedented 22.5% body weight reduction at 15mg.
Type 2 Diabetes
HighFDA-approved (Mounjaro). Exceptional HbA1c reduction with secondary weight loss surpassing other diabetes drugs.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| Pen (Mounjaro / Zepbound) | n/a (prefilled) | Device-labeled | Follow the pen. Do not recon a pen. |
| 10 mg compounded/research cake | 2.0 mL BAC | 5 mg/mL | 2.5 mg = 0.50 mL = 50 units on a U-100. This is not a Zepbound pen. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
FDA-approved for type 2 diabetes and weight management. Common side effects include nausea, diarrhea, and decreased appetite (typically during dose escalation). Same MTC/MEN 2 contraindications as semaglutide. Dose escalation over 20+ weeks minimizes GI side effects.
Regulatory & Legal Status
FDA-approved as Mounjaro® (T2D) and Zepbound® (obesity)
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Prescription Drug
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- SURMOUNT-1 22.5% is branded 15 mg, not a 10 mg compounded vial of unknown fill.
- SURPASS-2 compared 15 mg tirzepatide to 1 mg semaglutide, not 2.4 mg Wegovy. Do not weaponize that as “always beats sema.”
- Same MTC/MEN2 boxed-warning class as other GLP-1 RAs.
Human evidence
Strong · labeled SURMOUNT / SURPASS program
- SURMOUNT-1 showed up to 22.5% body weight reduction at branded 15 mg — not a compounded cake of unknown fill.
- FDA-approved as Mounjaro (T2D) and Zepbound (weight management).
- SURPASS-2 compared 15 mg tirzepatide to 1 mg semaglutide, not 2.4 mg Wegovy.
Verdict
Tirzepatide is the dual-agonist labeled drug. Use a pen under a clinician. A research cake is not Mounjaro. Do not stack it with semaglutide. It is not a recovery peptide.
Interactions & Contraindications
Same contraindications as semaglutide: MTC/MEN2 history. Do not combine with other GLP-1 or GIP agonists. MK-677 (and other GH secretagogues) may partially oppose insulin-sensitizing effects - monitor fasting glucose. Warfarin/anticoagulant patients should monitor INR during dose escalation.
Synergies & Common Stacks
BPC-157 may attenuate GI side effects of tirzepatide during dose escalation via gastroprotective and anti-inflammatory mechanisms.
In body recomposition protocols, tirzepatide drives fat loss while MK-677 supports GH-mediated muscle preservation - but monitor for insulin resistance interaction.
Tirzepatide vs. Semaglutide
Canonical comparison: Tirzepatide vs Semaglutide
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 agonist (single) |
| Peak Weight Loss | 22.5% (SURMOUNT-1) | 14.9–17% (STEP 1) |
| FDA Approval | Mounjaro® / Zepbound® | Ozempic® / Wegovy® |
| Half-Life | ~5 days | ~7 days |
| GI Side Effects | Similar nausea profile | Moderate nausea at escalation |
| Muscle Preservation | Better - GIP component preserves lean mass | Some lean mass loss reported |
Verdict: Tirzepatide outperforms semaglutide on weight loss endpoints in head-to-head analysis (SURPASS-2). If maximum fat loss while preserving muscle is the priority, tirzepatide is the superior agent.
Tirzepatide vs. Retatrutide
Canonical comparison: Tirzepatide vs Retatrutide
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 + GIP + Glucagon triple agonist |
| Peak Weight Loss | 22.5% (SURMOUNT-1) | 28.7%+ (TRIUMPH Phase 2/3 data) |
| FDA Status | Approved (Mounjaro® / Zepbound®) | Phase 3 (not yet approved) |
| Availability | Branded + compounded | Compounded only (investigational) |
| Safety Track Record | Extensive Phase 3 + real-world data | Phase 3 data emerging |
Verdict: Retatrutide shows superior weight loss in Phase 3 data via its triple agonist mechanism, but remains investigational. Tirzepatide is the FDA-approved gold standard for proven maximum weight loss as of 2026.
Appears in goal guides
Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.
Frequently Asked Questions
Pen or compounded vial?▼
What makes tirzepatide different from semaglutide?▼
What is the tirzepatide dose escalation schedule?▼
How do I calculate tirzepatide syringe units from a compounded vial?▼
References
- Jastreboff et al. “"Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)".” New England Journal of Medicine (2022). PMID: 35658024
- Frías et al. “"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)".” New England Journal of Medicine (2021). PMID: 34170647
📚 Related Articles
Get Tirzepatide from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review